Ashley N. Krepline

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Susan Tsai · 12 shared papers, 2014–2021 · strength 1.08
   • Paper Has Personalized Medicine for Pancreatic Cancer Arrived? DOI 10.1016/j.yasu.2019.04.006↗
   • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
   • Paper Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. DOI 10.1016/j.surg.2020.06.038↗
2. Bradley A. Erickson · 11 shared papers, 2014–2021 · strength 0.88
   • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
   • Paper Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. DOI 10.1016/j.surg.2020.06.038↗
   • Paper Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? DOI 10.1007/s11605-019-04423-6↗
3. Douglas B. Evans · 11 shared papers, 2014–2021 · strength 0.88
   • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
   • Paper Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. DOI 10.1016/j.surg.2020.06.038↗
   • Paper Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? DOI 10.1007/s11605-019-04423-6↗
4. Ben George · 10 shared papers, 2014–2021 · strength 0.81
   • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
   • Paper Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. DOI 10.1016/j.surg.2020.06.038↗
   • Paper Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? DOI 10.1007/s11605-019-04423-6↗
5. Kathleen K. Christians · 10 shared papers, 2014–2021 · strength 0.75
   • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
   • Paper Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? DOI 10.1007/s11605-019-04423-6↗
   • Paper Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. DOI 10.1016/j.hpb.2020.03.022↗
6. William Adrian Hall · 6 shared papers, 2017–2021 · strength 0.61
   • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
   • Paper Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. DOI 10.1016/j.surg.2020.06.038↗
   • Paper Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? DOI 10.1007/s11605-019-04423-6↗
7. Mohammed Aldakkak · 5 shared papers, 2015–2021 · strength 0.40
   • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
   • Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
   • Paper Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized… DOI 10.1007/s11605-016-3319-4↗
8. Callisia Nathelee Clarke · 2 shared papers, 2017–2020 · strength 0.16
   • Paper Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. DOI 10.1016/j.hpb.2020.03.022↗
   • Paper Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? DOI 10.1007/s11605-017-3544-5↗
9. Chad A. Barnes · 2 shared papers, 2017–2020 · strength 0.16
   • Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
   • Paper Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? DOI 10.1007/s11605-017-3544-5↗
10. Fabian Mc. Johnston · 3 shared papers, 2014–2015 · strength 0.14
    • Paper Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized… DOI 10.1111/hpb.12448↗
    • Paper Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. DOI 10.1016/j.surg.2015.06.017↗
    • Paper Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. DOI 10.1007/s11605-014-2635-9↗
11. Javier Mora · 1 shared paper, 2021 · strength 0.13
    • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
12. Naveen M. Kulkarni · 1 shared paper, 2021 · strength 0.13
    • Paper Adjuvant therapy rates and overall survival in patients with localized pancreatic cancer from high Area Deprivation Ind… DOI 10.1016/j.amjsurg.2020.12.001↗
13. Rebecca Y. Kim · 1 shared paper, 2021 · strength 0.12
    • Paper Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. DOI 10.1016/j.surg.2020.06.038↗
14. Mandana Kamgar · 1 shared paper, 2021 · strength 0.12
    • Paper Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer. DOI 10.1016/j.surg.2020.06.038↗
15. Lindsay A. Bliss · 1 shared paper, 2020 · strength 0.11
    • Paper Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice? DOI 10.1007/s11605-019-04423-6↗
16. D. Wittmann · 1 shared paper, 2020 · strength 0.10
    • Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
17. Catherine E. Hagen · 1 shared paper, 2020 · strength 0.10
    • Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
18. Kulwinder S. Dua · 1 shared paper, 2020 · strength 0.10
    • Paper Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. DOI 10.1097/sla.0000000000003049↗
19. Eunice S. Paul Rajamanickam · 1 shared paper, 2017 · strength 0.06
    • Paper Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized… DOI 10.1007/s11605-016-3319-4↗
20. Parag P. Tolat · 1 shared paper, 2016 · strength 0.06
    • Paper Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cance… DOI 10.1002/jso.24361↗
21. John Thomas Miura · 1 shared paper, 2015 · strength 0.05
    • Paper Use of neoadjuvant therapy in patients 75 years of age and older with pancreatic cancer. DOI 10.1016/j.surg.2015.06.017↗
22. Kiran Kalyan Turaga · 1 shared paper, 2014 · strength 0.04
    • Paper Patency rates of portal vein/superior mesenteric vein reconstruction after pancreatectomy for pancreatic cancer. DOI 10.1007/s11605-014-2635-9↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.